Antonio MD - GeneThera Chairman, Founder
| GTHR Stock | USD 0.0001 0.00 0.00% |
Insider
Antonio MD is Chairman, Founder of GeneThera
| Age | 68 |
| Phone | 720 587 5100 |
| Web | https://www.genethera.net |
GeneThera Management Efficiency
The company has return on total asset (ROA) of (95.3798) % which means that it has lost $95.3798 on every $100 spent on assets. This is way below average. GeneThera's management efficiency ratios could be used to measure how well GeneThera manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Christian Mueller | Immutep Ltd ADR | N/A | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Michelle MD | Verastem | 48 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| David Dornan | Elevation Oncology | 46 | |
| Stephen JD | Geron | 74 | |
| Shengfei Fang | Immutep Ltd ADR | N/A | |
| Erin Cox | Verastem | N/A | |
| Brian Sullivan | Elevation Oncology | N/A | |
| BPHARM RPh | Verastem | 63 | |
| Mba MBA | Verastem | 70 | |
| Piyush Gupta | Verastem | N/A | |
| Jonathan Pachter | Verastem | 66 | |
| Robert Weinberg | Verastem | N/A | |
| Wolfgang MD | Rigel Pharmaceuticals | 58 | |
| Daniel Calkins | Verastem | 36 | |
| Valerie MD | Elevation Oncology | 46 | |
| Sean Flynn | Verastem | 50 | |
Management Performance
| Return On Asset | -95.38 |
GeneThera Leadership Team
Elected by the shareholders, the GeneThera's board of directors comprises two types of representatives: GeneThera inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GeneThera. The board's role is to monitor GeneThera's management team and ensure that shareholders' interests are well served. GeneThera's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GeneThera's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antonio MD, Chairman, Founder | ||
| Tannya Irizarry, Chief Admin. Officer, Interim CFO, Interim Principal Accounting Officer and Secretary |
GeneThera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GeneThera a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -95.38 | |||
| Current Valuation | 1.44 M | |||
| Shares Outstanding | 35.33 M | |||
| Shares Owned By Insiders | 17.99 % | |||
| Price To Earning | (0.17) X | |||
| EBITDA | (1 M) | |||
| Net Income | (1.01 M) | |||
| Cash And Equivalents | 140.1 K | |||
| Total Debt | 806.87 K | |||
| Book Value Per Share | (0.24) X |
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.